We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
Read MoreHide Full Article
QIAGEN N.V. (QGEN - Free Report) recently announced the launch of therascreen PIK3CA RGQ PCR Kit, also known as therascreen PIK3CA Kit, for the treatment of breast cancer. The kit has received regulatory approval from the FDA as a companion diagnostic which treats with PIQRAY (alpelisib), a therapy developed and marketed by Novartis. The launch fortifies QIAGEN’s foothold in the field of cancer diagnosis.
More on therascreen PIK3CA Kit
The therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA for identification of activating mutations in the PIK3CA gene. It is also the first FDA approved test using plasma specimens as a liquid biopsy, which can enable one to make treatment decisions in breast cancer. The kit is equipped to identify 11 PIK3CA mutations, which are assumed to be present in approximately 40% of hormone receptor-positive advanced or metastatic breast cancer patients.
The real-time qualitative PCR kit is processed on QIAGEN’s Rotor-Gene Q MDx, a member of the modular QIAsymphony suite of automation solutions. The test uses QIAGEN’s global co-exclusive license from Johns Hopkins University for PCR-based companion diagnostics based on mutations in the PIK3CA gene.
QIAGEN collaborated with Novartis to develop the therascreen PIK3CA Kit and received FDA clearance along with the pharma company’s PIQRAY.
Recent Developments
Of late, QIAGEN has been investing in some crucial developments which are expected to strengthen its foothold in the cancer diagnosis and treatment market.
Earlier this month, QIAGEN collaborated with Inovio Pharmaceuticals to co-develop a companion diagnostic which can guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). This Precision Medicine partnership focuses on Inovio’s VGX-3100, a late-stage investigational product with possibility to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
Last month, QIAGEN announced the U.S. launch of its novel therascreen FGFR RGQ RT-PCR Kit as a companion diagnostic which can provide guidance in the use of the recently-approved FGFR kinase inhibitor, BALVERSA, developed by Janssen Biotech. The test will enable the identification of patients with urothelial cancer whose tumors have certain alterations in the fibroblast growth factor receptor 3 gene. The FDA co-approved the new test with BALVERSA.
Market prospects
Per Grand View Research, the global cancer diagnostics is expected to see a CAGR of 7% from 2019 to 2026. Hence QIAGEN’s latest launch is a well-timed one.
Price Performance
Over the past year, QIAGEN has outperformed its industry. The stock has rallied 5.2% against the industry’s 16.4% fall.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Bruker’s long-term earnings growth rate is estimated at 11.7%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
QIAGEN N.V. (QGEN - Free Report) recently announced the launch of therascreen PIK3CA RGQ PCR Kit, also known as therascreen PIK3CA Kit, for the treatment of breast cancer. The kit has received regulatory approval from the FDA as a companion diagnostic which treats with PIQRAY (alpelisib), a therapy developed and marketed by Novartis. The launch fortifies QIAGEN’s foothold in the field of cancer diagnosis.
More on therascreen PIK3CA Kit
The therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA for identification of activating mutations in the PIK3CA gene. It is also the first FDA approved test using plasma specimens as a liquid biopsy, which can enable one to make treatment decisions in breast cancer. The kit is equipped to identify 11 PIK3CA mutations, which are assumed to be present in approximately 40% of hormone receptor-positive advanced or metastatic breast cancer patients.
The real-time qualitative PCR kit is processed on QIAGEN’s Rotor-Gene Q MDx, a member of the modular QIAsymphony suite of automation solutions. The test uses QIAGEN’s global co-exclusive license from Johns Hopkins University for PCR-based companion diagnostics based on mutations in the PIK3CA gene.
QIAGEN collaborated with Novartis to develop the therascreen PIK3CA Kit and received FDA clearance along with the pharma company’s PIQRAY.
Recent Developments
Of late, QIAGEN has been investing in some crucial developments which are expected to strengthen its foothold in the cancer diagnosis and treatment market.
Earlier this month, QIAGEN collaborated with Inovio Pharmaceuticals to co-develop a companion diagnostic which can guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). This Precision Medicine partnership focuses on Inovio’s VGX-3100, a late-stage investigational product with possibility to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
Last month, QIAGEN announced the U.S. launch of its novel therascreen FGFR RGQ RT-PCR Kit as a companion diagnostic which can provide guidance in the use of the recently-approved FGFR kinase inhibitor, BALVERSA, developed by Janssen Biotech. The test will enable the identification of patients with urothelial cancer whose tumors have certain alterations in the fibroblast growth factor receptor 3 gene. The FDA co-approved the new test with BALVERSA.
Market prospects
Per Grand View Research, the global cancer diagnostics is expected to see a CAGR of 7% from 2019 to 2026. Hence QIAGEN’s latest launch is a well-timed one.
Price Performance
Over the past year, QIAGEN has outperformed its industry. The stock has rallied 5.2% against the industry’s 16.4% fall.
Zacks Rank and Key Picks
QIAGEN currently carries a Zacks Rank # 3 (Hold).
Some better-ranked stocks in the broader medical space are Cerner Corporation , Penumbra (PEN - Free Report) and Bruker Corporation (BRKR - Free Report) . While Cerner sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cerner’s long-term earnings growth rate is expected to be 13.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
Bruker’s long-term earnings growth rate is estimated at 11.7%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>